CEO’s 90‑Million‑Share Buy Signals Confidence Post‑Reverse Split

Insider Buying in the Wake of a Reverse Split

The recent reverse‑stock split executed on May 22, which reduced the share count by a factor of 20 while maintaining the company’s market capitalisation, has been immediately followed by a substantial purchase by CEO Bailey David F. In a single day the executive acquired more than 90 million shares at an average price of $5.58 per share, raising his ownership to roughly 3.12 million shares. The price paid is only marginally higher than the closing price of $5.40, indicating that the purchase was not an attempt to “front‑load” the market with a premium. Rather, the timing suggests that the management believes the current share price is materially undervalued, and that the company’s underlying business—particularly its healthcare platform—will rebound from the dramatic valuation reset.

What Investors Should Read Between the Lines

The reverse split was a tactical measure designed to maintain the company’s listing on Nasdaq. The manoeuvre exposed the stock to a “price shock” that saw the share value drop from roughly $70 to $4.70. The CEO’s bulk purchase, occurring immediately after the split, is a textbook signal that senior management believes the share price is below its intrinsic value.

For investors, this may mean that the company is positioning itself for a rebound once it resolves immediate liquidity concerns and re‑establishes a sustainable growth trajectory. However, key risks remain. The company’s market capitalisation is only $95 million, and quarterly earnings are still unreported in the filing. Consequently, the buy may be more of a defensive maneuver than a speculative bet.

A Profile of the CEO’s Insider Activity

Bailey David F’s historical trading record shows a pattern of large‑volume purchases. In February 2026, the CEO bought 108 million shares at $0.00—a likely “grant” or “vest” transaction rather than a market purchase. Since then, his holdings have hovered between 3.0 million and 3.1 million shares following the reverse split. Compared to other insiders, such as CTO Evans Tyler Matthew, who has recently bought multiple option blocks, Bailey’s activity is more concentrated and focused on common stock, indicating a preference for direct equity exposure over derivative instruments.

Implications for the Company’s Future

The combined effect of a reverse split and a sizable insider buy is twofold.

1. Confidence Signal – The CEO’s stake provides a vote of confidence that may reassure a jittery investor base.
2. Lock‑in Effect – It potentially creates a “lock‑in” effect, where management is less likely to sell shares during a downturn.

If the company can leverage its healthcare services portfolio to generate new revenue streams, the stock could begin to climb from its all‑time low. Until then, the stock remains a high‑risk play, best suited for investors who can stomach volatility while watching for any sign of a strategic turnaround.